Diagnostic Imaging's Top Five Prostate Imaging Content of 2024
Catch up on the most well-viewed prostate imaging content from 2024.
As we come to the end of 2024, we take a look back at the most well-read prostate imaging content with topics ranging from predictive factors for metastatic prostate cancer to the use of prostate MRI for active surveillance and PSMA PET/CT-guided radiotherapy for oligometastatic prostate cancer. Review the slideshow below to see highlighted prostate imaging content from the past year.
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
Is MRI Contrast Enhancement Necessary for Long-Term Monitoring of Diffuse Glioma?
March 4th 2025In a comparison of contrast-enhanced T1-weighted (CET1w) MRI (and T2-weighted MRI/FLAIR imaging, researchers found that only three out of 82 cases of glioma progression were solely detected with CET1w MRI.
Emerging AI Software for Prostate MRI Offers 95 Percent Sensitivity for csPCa
February 28th 2025In a multicenter study involving over 1,000 patients, a deep learning software offered comparable sensitivity and specificity for Gleason grade group > 2 tumors in comparison to radiologist interpretation.
